Ultragenyx Pharmaceutical Inc.
RARE
$26.96
$0.160.60%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -10.00% | -10.86% | -1.05% | -3.69% | 8.96% |
| Total Depreciation and Amortization | -8.00% | -4.88% | -1.69% | 4.21% | 9.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -8.54% | -12.73% | -7.73% | -2.18% | -5.32% |
| Change in Net Operating Assets | 3.10% | -232.34% | -268.24% | -129.26% | -7.56% |
| Cash from Operations | -15.18% | -27.74% | -12.62% | -6.49% | 10.26% |
| Capital Expenditure | 27.06% | -29.80% | 11.20% | 35.51% | 45.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 85.66% | 492.12% | 2,301.37% | 289.94% | -80.63% |
| Cash from Investing | 121.85% | 784.80% | 1,410.75% | 280.51% | -83.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -94.30% | -78.01% | -78.01% | -87.92% | -87.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 5,500.00% | 5,453.98% | 5,500.00% | -100.00% | -- |
| Cash from Financing | 304.16% | 19.78% | 19.89% | -88.01% | -86.73% |
| Foreign Exchange rate Adjustments | -108.37% | 921.81% | 331.90% | 218.36% | 560.32% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 83.88% | 196.64% | 821.47% | -32.31% | -178.64% |